They now have a Dollars 125 price target on the stock.
Headquartered in Westbrook, IDEXX employs more than 6,000 people.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Huntington National Bank boosted its position in Idexx Laboratories by 112.1% in the second quarter. BlackRock Institutional Trust Company N.A. increased its position in IDEXX Laboratories by 24.9% in the second quarter. The company's stock has a Return on Assets (ROA) of -1.1 percent, a Return on Equity (ROE) of -2.5 percent and Return on Investment (ROI) of 0.7 percent.
04/01/2016 - IDEXX Laboratories, Inc. had its "neutral" rating reiterated by analysts at CL King.
In the last trading session, The Company traded 20.57 Million shares. Finally, Tredje AP fonden purchased a new position in Idexx Laboratories during the second quarter valued at about $175,000. In the last 27 earnings reports, the company has topped earnings-per-share estimates 75% percent of times.
Considering the performance, IDEXX Laboratories, Inc. (NASDAQ:IDXX) according to Finviz Data is $2.35. The Market Cap of the company stands at 10.47 Billion. The Stock Market opened sessions at 118.02 and closed at 115.95. IDEXX Laboratories, Inc. has a 52-week low of 63.48 and a 52-week high of 121.77. The stock's price moved up its 200-day moving average of $43.85.
The 6 analysts offering 12-month price forecasts for IDEXX Laboratories Inc have a median target of 123.50, with a high estimate of 126.00 and a low estimate of 91.00. (NASDAQ:IDXX) was down -1.40% during the last day of trading, with a day high of 0.00.
For the current quarter, the highest estimate analysts provided is 439.5 Million and the lowest is 432.13 Million. Company net profit margin stands at 14.70%. The business's revenue for the quarter was up 10.3% compared to the same quarter a year ago. According to them, the median (average) EPS the company could deliver is 0.51/share. Analyst's mean target price for the firm is $6.50 while analysts mean recommendation is 2.00.
TRADEMARK VIOLATION WARNING: This story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. Zacks Investment Research downgraded shares of IDEXX Laboratories from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, October 4th. (NASDAQ:IDXX) recently. The rating firm issued a Neutral rating to this company in a research note released on Aug 03, 2016. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $105.20. (NASDAQ:IDXX) recently. The rating firm gave a Neutral rating to this stock in a research note published on April 01, 2016. The consensus recommendation by Thomson Reuters Analysts is Buy for CCE and their mean rating for the stock is 1.00 on scale of 1-5. This transaction occurred on 2016-11-09 totals $4314000. (NASDAQ:CME) for the next year 5 years is 7.28 percent (per annum), as compared to 7.74 percent (per annum) in the past 5 years. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
In related news, Chairman Jonathan W. Ayers sold 40,000 shares of the firm's stock in a transaction dated Wednesday, November 9th.